Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab have improved outcomes in metastatic renal cell carcinoma (mRCC) patients, but they are also associated with immune-related adverse events (irAEs). As observed in melanoma, we hypothesized that patients experiencing an autoimmune r...
Saved in:
| Main Authors: | Raquibul Hannan, Alana Christie, Payal Kapur, James Brugarolas, Hans Hammers, Viral Patel, Roy Elias, Joseph Formella, William Schwartzman, Qi Cai, Venkat Malladi, Miguel Vazquez, Renee McKay, Ivan Pedrosa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001198.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
by: Jose Lutzky, et al.
Published: (2017-11-01) -
Brentuximab-Induced Acute Interstitial Nephritis: A Case Report
by: Matthew Patterson, et al.
Published: (2024-11-01) -
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
by: Yu Yamamoto, et al.
Published: (2022-03-01) -
Sildenafil Induced Acute Interstitial Nephritis
by: Ryan Burkhart, et al.
Published: (2015-01-01) -
Reversible Fluindione-Induced Chronic Interstitial Nephritis
by: Thomas Crepin, et al.
Published: (2016-01-01)